Squarepoint Ops LLC Has $67.60 Million Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Squarepoint Ops LLC lifted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 108.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 163,510 shares of the company's stock after buying an additional 85,214 shares during the period. Squarepoint Ops LLC owned about 0.20% of IDEXX Laboratories worth $67,602,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Hurley Capital LLC acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth $29,000. Rialto Wealth Management LLC acquired a new position in IDEXX Laboratories in the 4th quarter worth about $30,000. Colonial Trust Co SC increased its holdings in IDEXX Laboratories by 84.8% in the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after purchasing an additional 39 shares in the last quarter. Kestra Investment Management LLC acquired a new position in IDEXX Laboratories in the 4th quarter worth about $38,000. Finally, Itau Unibanco Holding S.A. increased its holdings in IDEXX Laboratories by 540.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock worth $40,000 after purchasing an additional 81 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Trading Up 0.7%

Shares of IDXX stock opened at $521.68 on Tuesday. The stock has a market cap of $41.95 billion, a price-to-earnings ratio of 48.89, a PEG ratio of 3.41 and a beta of 1.52. The stock has a 50-day moving average of $433.47 and a 200-day moving average of $432.18. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $545.43.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The company had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. During the same quarter in the prior year, the company earned $2.71 EPS. The firm's revenue for the quarter was up 3.6% compared to the same quarter last year. On average, equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Analysts Set New Price Targets

IDXX has been the subject of a number of recent research reports. Morgan Stanley upped their target price on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a report on Monday, May 5th. Barclays upped their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Stifel Nicolaus upped their target price on IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a report on Monday. Piper Sandler upped their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Finally, Bank of America upped their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, IDEXX Laboratories has a consensus rating of "Moderate Buy" and a consensus target price of $536.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.